• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Spruce Biosciences, Inc. - Common Stock (NQ:SPRB)

    58.65 +7.07 (+13.71%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 138,315
    Open 53.04
    Bid (Size) 55.00 (300)
    Ask (Size) 66.00 (200)
    Prev. Close 51.58
    Today's Range 51.16 - 58.92
    52wk Range 7.260 - 240.00
    Shares Outstanding 40,710,692
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
    From Spruce Biosciences, Inc.
    Via Business Wire

    Performance

    YTD
    -35.3%
    -35.3%
    1 Month
    +36.1%
    +36.1%
    3 Month
    +13.2%
    +13.2%
    6 Month
    +9.5%
    +9.5%
    1 Year
    +498.5%
    +498.5%

    More News

    Read More
    News headline image
    Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Joins the Russell 3000® Index
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences to Participate in Upcoming Conferences in June
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences to Present at Upcoming Investor Conferences in March
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy ↗
    Via Stocktwits
    News headline image
    Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
    From Spruce Biosciences, Inc.
    Via Business Wire
    News headline image
    Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
    From Spruce Biosciences, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Spruce Biosciences, Inc. - Common Stock publicly traded?
    Yes, Spruce Biosciences, Inc. - Common Stock is publicly traded.
    What exchange does Spruce Biosciences, Inc. - Common Stock trade on?
    Spruce Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Spruce Biosciences, Inc. - Common Stock?
    The ticker symbol for Spruce Biosciences, Inc. - Common Stock is SPRB on the Nasdaq Stock Market
    What is the current price of Spruce Biosciences, Inc. - Common Stock?
    The current price of Spruce Biosciences, Inc. - Common Stock is 58.65
    When was Spruce Biosciences, Inc. - Common Stock last traded?
    The last trade of Spruce Biosciences, Inc. - Common Stock was at 08/24/26 04:00 PM ET
    What is the market capitalization of Spruce Biosciences, Inc. - Common Stock?
    The market capitalization of Spruce Biosciences, Inc. - Common Stock is 2.39B
    How many shares of Spruce Biosciences, Inc. - Common Stock are outstanding?
    Spruce Biosciences, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.